Aseptix signs global technology licensing agreement with Ecolab
Ecolab will acquire the Professional Products Division of Aseptix, which is active in the healthcare, food processing and pharma industries
Aseptix Health Sciences, a specialist in next-generation antimicrobials headquartered in the Netherlands, has signed a global licensing agreement with hygiene company Ecolab.
Under the agreement, Ecolab will acquire a global licence for Professional Markets on Aseptix technologies as well as the Dutch company’s Professional Products Division.
Aseptix currently sells its Aseptix-branded professional products in Europe and India, mainly to healthcare, food processing and pharmaceutical clients.
No financial details have been revealed.
This is a major milestone for Aseptix
Aseptix is the inventor of activated hydrogen peroxide technologies which are used to eradicate numerous pathogens. The active ingredient degrades to water and oxygen after use. Among its clients are Clorox, SCA (Tork), Initial and Reckitt Benckiser (Scholl).
Under the agreement Aseptix will continue to own more than 60 patents around its technologies and related know-how, while Ecolab will receive exclusive rights for use of the majority of Aseptix’s technologies in professional markets around the world.
Aseptix says this will allow it to remain independent and capitalise on its proven technologies for consumer applications across many markets globally.
The agreement also fits the company’s strategy of globalising its technology and creating a new global standard in infection prevention. With the growth in hospital acquired infections (HAIs) and increasing focus on clean environments, the company says the relevance of these types of solutions is rapidly increasing.
The Aseptix technology offers a broad efficacy spectrum and short contact times, is safer for people and the environment, and is easy to use.
Ilja Bobbert, founder and CEO of Aseptix, said: ‘This is a major milestone for Aseptix. Aseptix has laid the initial groundwork and has proven that the products can lower infection rates in many industries. Now, Ecolab can truly globalise the technology across its business segments and geographies worldwide.’
